MoneyWorks4Me

Dr.Reddys Laboratories informs about financial statements

04 Feb 2019 Evaluate

Dr.Reddys Laboratories has informed that the Company has filed its unaudited condensed consolidated interim financial statements prepared under IFRS in Form 6-K for the quarter ended December 31, 2018, with the United States Securities and Exchange Commission on February 1, 2019. A copy of the Form 6-K is been attached.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1783.25
Dr. Reddys Labs. 1202.40
Cipla 1329.50
Lupin 2007.10
Zydus Lifesciences 1154.00
View more..